# A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

> **NCT06519357** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia** · enrollment: 23 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** Lamivudine 300 MG

## Key facts

- **NCT ID:** NCT06519357
- **Lead sponsor:** Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-28
- **Primary completion:** 2025-09-05
- **Final completion:** 2026-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519357, "A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06519357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*